According to the researchers, “the increase in antibody levels that we saw with both Moderna and Pfizer is slightly higher than what we saw following the third booster shot.”
Jerusalem, Jan 17 (EFE).- The fourth dose from COVID vaccine it’s just “partially effective” with the Omicron variant, according to preliminary results from an Israeli Sheba Medical Center study with a booster dose from both Pfizer and Moderna.
“Despite increased antibody levels, the fourth vaccine offers only partial defense once morest the virus. Thus, the vaccines (Pfizer/Moderna), which were more effective once morest previous variants, offer less protection once morest Ómicron”, Gili Regev-Yochay, who is leading the investigation, announced today.
The trial was conducted among 154 Sheba medical staff who received a Pfizer dose and 120 others who were inoculated with the Moderna dose.
© Provided by However
A person receives the coronavirus vaccine at the Clalit Medical Center in Mevaseret Zion, Israel, on January 11, 2022. Photo: Maya Alleruzzo, AP
All volunteers were previously vaccinated with the three doses of Pfizer.
“The trials showed that one week following people received the Moderna vaccine, the increase in antibody levels was similar to that of those who received Pfizer’s fourth vaccine,” concludes this first trial.
Furthermore, the research showed that, two weeks following receiving Pfizer’s fourth vaccine, “antibody levels continued to rise slightly following the first week.”
“The increase in antibody levels that we saw with both Moderna and Pfizer is slightly higher than what we saw following the third booster vaccine,” says Regev-Yochay, director of the Infectious Diseases Unit, which however detects a lower effectiveness with current dominant variant.
